Last reviewed · How we verify
A Study of Patient Characteristics, Co-Morbidities, and Treatment Patterns in Chronic Myeloid Leukemia Patients in Kuwait
The aim of this study is to assess demographics, clinical features, treatment patterns, and the comorbidity burden and its impact on CML patients in the real-world clinical setting in Kuwait. Adult patients with Philadelphia positive-chromosome (Ph+ve) CML who have received at least one line of tyrosine kinase inhibitor (TKI) treatment, such as but not limited to imatinib, dasatinib, nilotinib, bosutinib, ponatinib, and asciminib will be included. The study will use data from the hospital records of CML patients between January 2014 and January 2024.
Details
| Lead sponsor | Novartis Pharmaceuticals |
|---|---|
| Status | NOT_YET_RECRUITING |
| Enrolment | 400 |
| Start date | Sat May 16 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Sat Sep 19 2026 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Leukemia, Myeloid, Chronic-Phase